Insight Therapeutics, LLC
Norfolk, Virginia, 23510, United States
NCT Number: NCT02882100
This study is powered to prospectively evaluate the relative effectiveness of adjuvanted trivalent influenza vaccine (aTIV; FLUAD) in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the commercially available, standard dose trivalent seasonal influenza vaccine (TIV; Fluvirin).
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Phase 4
Norfolk, Virginia, 23510, United States
SUMMARY: A random study sample of up to 1000 NHs within 75 miles of the local area of the 121 cities where the CDC performs weekly influenza surveillance (estimated N= 11,239) may be offered the opportunity for participation; the first 1000 eligible to participate and accepting the offer will be enrolled. Participating facilities will be offered vaccine education for residents and staff, but will be randomly allocated to receive aTIV (FLUAD) vaccine or usual care (TIV) vaccination for their residents.
BACKGROUND: Lower respiratory tract infection (LRI), including pneumonia, bronchitis, and tracheobronchitis, is the leading cause of infectious mortality and hospitalization in older adults , and nursing home (NH) residents. Pneumonia and infection often produce attenuated signs and symptoms in older adults, leading to delayed or even misdiagnosis for this population. Diagnosis is further compromised due to few and sporadic clinician visits with nursing home residents, and reduced access to radiology. LRI may or may not directly lead to hospitalization, but LRIs are associated with considerable other morbidity than can result in hospitalization, including exacerbation of underlying cardiopulmonary diseases. Hospitalization rates for NH residents vary considerably between facilities, but the majority of hospitalizations occur during the 12 weeks during which influenza peaks each year.
OBJECTIVES: The primary objective is to estimate the differences in hospitalization rates during influenza season experienced by long-stay nursing home residents, between facilities using adjuvanted trivalent vaccine vs. standard trivalent vaccine. The secondary objective is to estimate the differences in the likelihood of Activities of Daily Living (ADL) functional decline and mortality rates in the study nursing homes, and influenza outbreaks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
Other names: Fluad, aTIV
Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
Other names: Fluvirin, TIV
Time frame: up to 1 year
Time to first occurrence of hospitalization for a respiratory-related Illness based upon Medicare inpatient hospital claims
Time frame: up to 1 year
Time to first occurrence of hospitalization for all-causes
Time frame: up to 1 year
Change in activities of daily living (ADL) scores
Time frame: up to 1 year
Difference in mortality rate
Time frame: up to 1 year
Difference in occurrence of documented influenza outbreaks
Insight Therapeutics, LLC
Other
Adjuvanted Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03274310
Acute Respiratory Infection, Infections
New York, United States
View Trial DetailsNCT03599739
Infections, Influenza
Norfolk, Virginia, United States
View Trial DetailsNCT02302924
Infections, Influenza
San Diego, California, United States
View Trial DetailsNCT02979730
Infections, Influenza
Boston, Massachusetts, United States
View Trial Details